AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gapped up before the market opened on Tuesday . The stock had previously closed at $2.93, but opened at $2.91. AVEO Pharmaceuticals shares last traded at $2.91, with a volume of 1107670 shares.
A number of equities research analysts have weighed in on the stock. BidaskClub downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 27th. B. Riley reiterated a “buy” rating and set a $5.00 price target on shares of AVEO Pharmaceuticals in a research note on Tuesday, January 16th. Finally, Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $4.05.
The company has a debt-to-equity ratio of -0.45, a current ratio of 1.56 and a quick ratio of 1.56.
ILLEGAL ACTIVITY WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/03/22/aveo-pharmaceuticals-aveo-shares-gap-up-to-2-91.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.